(Q43024228)

12 November 2017

title

Liver transcriptomic changes associated with ritonavir-induced hyperlipidemia in sensitive and resistant strains of rats (English)

1 reference

12 November 2017

0 references

1 reference

1 reference

Yi Yang

1

1 reference

12 November 2017

Annette J Dahly-Vernon

2

1 reference

12 November 2017

Eric A G Blomme

3

1 reference

12 November 2017

Jie Lai-Zhang

4

1 reference

12 November 2017

Dale J Kempf

5

1 reference

12 November 2017

Kennan C Marsh

6

1 reference

12 November 2017

Yvette A Harrington

7

1 reference

12 November 2017

Steven H Nye

8

1 reference

12 November 2017

Darin L Evans

9

1 reference

12 November 2017

Richard J Roman

10

1 reference

12 November 2017

Howard J Jacob

11

1 reference

12 November 2017

Jeffrey F Waring

12

1 reference

12 November 2017

publication date

23 May 2010

1 reference

12 November 2017

published in

The Veterinary Journal

1 reference

12 November 2017

volume

185

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

75-82

1 reference

Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Effects of fibrates on serum metabolic parameters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Lipid abnormalities in a never-treated HIV-1 subtype C-infected African population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Nutritional and hormonal regulation of mRNA levels of lipogenic enzymes in primary cultures of rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

HIV protease inhibitor ritonavir induces lipoatrophy in male mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Effects of HIV protease inhibitor therapy on lipid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Confounding factors in toxicity testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Half-life of cholesterol 7alpha-hydroxylase activity and enzyme mass differ in animals and humans when determined by a monoclonal antibody against human cholesterol 7alpha-hydroxylase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Primary structure and inducibility by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) of aryl hydrocarbon receptor repressor in a TCDD-sensitive and a TCDD-resistant rat strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

The effects of HIV protease inhibitors on carbohydrate and lipid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

HIV protease inhibitors stimulate hepatic triglyceride synthesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Recent developments in HIV protease inhibitor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Metabolic issues associated with protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

HIV protease inhibitors-induced atherosclerosis: prevention by alpha-tocopherol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Enzymes in the conversion of cholesterol into bile acids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Effects of CYP7A1 overexpression on cholesterol and bile acid homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

HIV, HAART, and hyperlipidemia: balancing the effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor alpha coregulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.017

10.1016/J.TVJL.2010.04.017

7 January 2021

Identifiers

DOI

1 reference

12 November 2017

1 reference